Current and historical daily PE Ratio for LIXTW ( Lixte Biotechnology Holdings Inc ) from 2020 to Jun 18 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Lixte Biotechnology stock (LIXTW) PE ratio as of Jun 18 2024 is 9999. More Details

Lixte Biotechnology Holdings Inc (LIXTW) PE Ratio (TTM) Chart

Lixte Biotechnology Holdings Inc (LIXTW) PE Ratio (TTM) Historical Data

View and export this data going back to 2020. Start your Free Trial

Total 0

Lixte Biotechnology PE Ratio (TTM) Historical Data
Date	PE Ratio (TTM) Data	Date	PE Ratio (TTM) Data

Lixte Biotechnology Holdings Inc (LIXTW) PE Ratio (TTM) Comparison

Company	Market Cap(Mil)	PE Ratio (TTM)

Business Description

Lixte Biotechnology Holdings Inc

NAICS : 325412 SIC : 2834

https://www.lixte.com

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Share Class Description:

LIXTW: Warrants (01/01/2025)

Compare

SONNXBIOFRTXEMMABCELPALITCONMNPRNAVBXCUROCSE:NOVO BVRTXREGNASX:CSLSGENXKRX:207940MRNAXKRX:068270BNTXALNY

Traded in other countries / regions

LIXT.USA8640.Germany

IPO Date

2020-11-19

Description

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.